Printer Friendly
The Free Library
5,677,147 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Interneuron Pharmaceuticals, Inc. dated Dec. 17, 1999.


--(BUSINESS WIRE)--

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.

-0-

Published Date:   Dec. 17, 1999

Company Name:     Interneuron Pharmaceuticals, Inc.

Address:          99 Hayden Avenue
                  Suite 200
                  Lexington, Massachusetts 02421-7966

Main Telephone
 Number:          781-861-8444

Internet Home
 Page Address
  (URL)           www.interneuron.com

Chief Executive
 Officer:         Glenn L. Cooper, M.D.

Chief Financial
 Officer:         Michael Rogers

Investor Relations/
Public Relations
 Contact:         William B. Boni
 Business number: 781-402-3410

Industry:         Biopharmaceuticals

Exchange/symbol:  NASDAQ:IPIC


Company description: Interneuron interneuron /in·ter·neu·ron/ (-noor´on)
1. a neuron between the primary sensory neuron and the final motoneuron.

2.
 Pharmaceuticals is engaged in the development and commercialization of a portfolio of products and product candidates for central nervous system and other disorders, including multiple compounds in late-stage clinical development.

Interneuron's product portfolio includes CerAxon (citicoline Citicoline (INN, also known as cytidine diphosphate choline and cytidine 5'-diphosphocholine) is a psychostimulant/nootropic.

It is an intermediate in the generation of phosphatidylcholine from choline.
) for stroke, pagoclone Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to  for panic and anxiety disorders Anxiety disorders

A group of distinct psychiatric disorders characterized by marked emotional distress and social impairment, including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and posttraumatic stress disorder.
, IP501 for liver disease Liver Disease Definition

Liver disease is a general term for any damage that reduces the functioning of the liver.
Description

The liver is a large, solid organ located in the upper right-hand side of the abdomen.
 and trospium for overactive bladder Overactive Bladder Definition

Overactive bladder is the leakage of large amounts of urine at unexpected times, including during sleep.
Description
 disorders. The company's development partners include Takeda Chemical Industries, Ltd for CerAxon.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 17, 1999
Words:171
Previous Article:Invesco Private Capital and Transpac Capital Lead $20 Million Funding of StarVox, Inc.; Prominent Venture Capital Firms Invest in IP Telephony...
Next Article:Corporate Profile for Alexander Marketing Services, dated Dec. 17, 1999.
Topics:



Related Articles
Interneuron Pharmaceuticals announces first quarter results.
Interneuron raises $11.5 million in financings, extends Class B warrants.
Panel OKs diet drug. (Food and Drug Administration advisory panel recommends approval of dexfenfluramine)(Science News of the Week)(Brief Article)
Interneuron Pharmaceuticals announces first quarter results; Confirms expiration date of Class B Warrants.
Corporate Profile for Interneuron Pharmaceuticals, dated March 22, 1996.
Interneuron Receives Preliminary Approval of Securities Litigation Settlement.
Interneuron Licenses Worldwide Rights for Pagoclone to Warner-Lambert for Panic and Generalized Anxiety Disorders.
Interneuron Pharmaceuticals Announces Fiscal 1999 Year End Results.
Interneuron Announces Clinical and Regulatory Plans for Trospium; Phase 3 Program to Consist of One Additional Clinical Trial of Urinary Incontinence...
Interneuron Pharmaceuticals Announces First Quarter Fiscal 2001 Results.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles